Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ
40.18
-1.83 (-4.36%)
Closed
Oct 14, 2026
Day's Range
39.9743.26
52 wk Range
39.9759.68
Financial Statements - SUPN - Supernus Pharmaceuticals, Inc.
Revenue
718.95M▲ 8.6%
Net Income
-38.55M▼ 152.2%Net Margin -5.4%
EBITDA
67.95M▼ 60.5%
Free Cash Flow
45.99M▼ 73.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 718.95M | 661.81M | 607.52M | 667.23M | 579.77M | 520.39M |
| Cost of Goods | 74.56M | 77.90M | 83.77M | 87.22M | 75.06M | 52.45M |
| Gross Profit | 644.39M | 583.91M | 523.74M | 580.01M | 504.71M | 467.93M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -36.86M | 75.55M | 13.40M | 45.61M | 79.49M | 175.59M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -25.41M | 6.11M | -18.67M | 510K | 6.53M | -1.90M |
| Pre Tax Income | -49.03M | 97.87M | 2.76M | 60.74M | 73.17M | 168.64M |
| Income Tax | -10.48M | 24M | 1.45M | 32K | 19.75M | 41.69M |
| Net Income | -38.55M | 73.86M | 1.31M | 60.71M | 53.42M | 126.95M |
| EPS Basic | -0.68 | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 |
| EPS Diluted | -0.68 | 1.32 | 0.02 | 1.04 | 0.98 | 2.36 |
| Basic Shares Outstanding | 56.45M | 55.10M | 54.53M | 53.66M | 53.09M | 52.61M |
| Diluted Shares Outstanding | 56.45M | 55.10M | 54.53M | 53.66M | 53.09M | 52.61M |
| Ebit | -49.03M | 97.87M | 5.18M | 67.81M | 96.59M | 192.40M |
| Ebitda | 67.95M | 172.17M | 108.71M | 152.84M | 122.66M | 212.44M |
| Net Income Continuous Operations | -38.55M | 73.86M | 1.31M | 60.71M | 53.42M | 126.95M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
